GW Henssler & Associates Ltd. acquired a new position in CVS Health Corporation (NYSE:CVS - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 4,334 shares of the pharmacy operator's stock, valued at approximately $294,000.
Other large investors also recently modified their holdings of the company. McIlrath & Eck LLC raised its holdings in shares of CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares during the period. Saudi Central Bank purchased a new stake in shares of CVS Health during the 1st quarter valued at about $34,000. Costello Asset Management INC raised its holdings in shares of CVS Health by 281.3% during the 1st quarter. Costello Asset Management INC now owns 572 shares of the pharmacy operator's stock valued at $39,000 after buying an additional 422 shares during the period. Stone House Investment Management LLC purchased a new stake in shares of CVS Health during the 1st quarter valued at about $39,000. Finally, Park Square Financial Group LLC purchased a new stake in shares of CVS Health during the 4th quarter valued at about $43,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.
CVS Health Stock Performance
CVS traded up $0.07 during trading on Friday, reaching $73.76. 5,074,859 shares of the company were exchanged, compared to its average volume of 5,804,935. The stock has a market cap of $93.56 billion, a P/E ratio of 20.60, a PEG ratio of 0.81 and a beta of 0.62. The firm has a 50 day moving average of $66.60 and a 200 day moving average of $66.00. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $74.53.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.46 by $0.35. The firm had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The firm's revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.
CVS Health Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Tuesday, July 22nd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.6%. The ex-dividend date was Tuesday, July 22nd. CVS Health's dividend payout ratio is presently 74.30%.
Insider Buying and Selling
In related news, Director Anne A. Finucane sold 7,500 shares of the company's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. This represents a 25.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.22% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on CVS shares. Cowen reiterated a "buy" rating on shares of CVS Health in a report on Monday, August 4th. Sanford C. Bernstein raised their target price on CVS Health from $72.00 to $77.00 and gave the company a "market perform" rating in a report on Friday. Morgan Stanley raised their target price on CVS Health from $80.00 to $82.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Truist Financial lifted their price objective on CVS Health from $82.00 to $84.00 and gave the stock a "buy" rating in a report on Monday, May 12th. Finally, Barclays lifted their price objective on CVS Health from $80.00 to $87.00 and gave the stock an "overweight" rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $77.89.
Get Our Latest Stock Report on CVS Health
About CVS Health
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
